longicin: isolated from Asimina longifolia; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Asimina | genus | A plant genus of the family ANNONACEAE. It has edible fruit and seeds which contain asitrocin, asitrilobins, and other tetrahydrofuran acetogenins.[MeSH] | Annonaceae | The custard-apple plant family of the order Magnoliales, subclass Magnoliidae, class Magnoliopsida. Some members provide large pulpy fruits and commercial timber. Leaves and wood are often fragrant. Leaves are simple, with smooth margins, and alternately arranged in two rows along the stems.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 10031452 |
| CHEMBL ID | 499805 |
| MeSH ID | M0254945 |
| Synonym |
|---|
| longicin |
| CHEMBL499805 |
| (2s)-2-methyl-4-[(2r,8r,11r)-2,8,11-trihydroxy-11-[(2r,5r)-5-[(1s)-1-hydroxypentadecyl]oxolan-2-yl]undecyl]-2h-furan-5-one |
| AKOS040752664 |
Longicin is a defensin-like peptide, identified from the midgut epithelium of hard tick Haemaphysalis longicornis.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Longicin is a defensin-like peptide, identified from the midgut epithelium of hard tick Haemaphysalis longicornis. " | ( Virucidal activity of Haemaphysalis longicornis longicin P4 peptide against tick-borne encephalitis virus surrogate Langat virus. Fujisaki, K; Galay, RL; Hernandez, EP; Kusakisako, K; Maeda, H; Mochizuki, M; Talactac, MR; Tanaka, T; Tsuji, N; Yoshii, K, 2016) | 2.13 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID398716 | Cytotoxicity against human PC3 cells after 7 days by MTT assay | 1995 | Journal of natural products, Sep, Volume: 58, Issue:9 | Longicin and goniothalamicinone: novel bioactive monotetrahydrofuran acetogenins from Asimina longifolia. |
| AID398719 | Cytotoxicity against human A498 cells after 7 days by MTT assay | 1995 | Journal of natural products, Sep, Volume: 58, Issue:9 | Longicin and goniothalamicinone: novel bioactive monotetrahydrofuran acetogenins from Asimina longifolia. |
| AID398713 | Cytotoxicity against human A549 cells after 7 days by MTT assay | 1995 | Journal of natural products, Sep, Volume: 58, Issue:9 | Longicin and goniothalamicinone: novel bioactive monotetrahydrofuran acetogenins from Asimina longifolia. |
| AID398718 | Cytotoxicity against human HT-29 cells after 7 days by MTT assay | 1995 | Journal of natural products, Sep, Volume: 58, Issue:9 | Longicin and goniothalamicinone: novel bioactive monotetrahydrofuran acetogenins from Asimina longifolia. |
| AID398717 | Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay | 1995 | Journal of natural products, Sep, Volume: 58, Issue:9 | Longicin and goniothalamicinone: novel bioactive monotetrahydrofuran acetogenins from Asimina longifolia. |
| AID398714 | Cytotoxicity against human MCF7 cells after 7 days by MTT assay | 1995 | Journal of natural products, Sep, Volume: 58, Issue:9 | Longicin and goniothalamicinone: novel bioactive monotetrahydrofuran acetogenins from Asimina longifolia. |
| AID398715 | Toxicity to brine shrimp | 1995 | Journal of natural products, Sep, Volume: 58, Issue:9 | Longicin and goniothalamicinone: novel bioactive monotetrahydrofuran acetogenins from Asimina longifolia. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||